Christiana Care offers Fast Breast MRI to Women with Dense Breast Tissue or Intermediate Risk of Breast Cancer
New supplemental screening option for increased breast cancer detection (Wilmington, Del. – July 1, 2019)The Christiana Care Breast Center at the Helen F. Graham Cancer Center & Research Institute is the first in Delaware to offer Fast Breast MRI to women with dense breast tissue or intermediate lifetime risk of developing breast cancer.Mammography has been shown to decrease breast cancer mortality, but it is less effective at detecting breast cancer in women with dense breast tissue. This limitation has prompted women with increased breast density to request supplemental screening.Breast MRI detects more breast cancers than other screening options. It has traditionally only been available to women at high risk of breast cancer, such as those with a strong family history or genetic mutation.Fast Breast MRI is a shortened version of a conventional MRI, taking approximately 10 minutes. Studies have shown that Fast Breast MRI maintains a high cancer detection rate, making it a valuable option for women who want additional breast cancer screening but do not qualify for conventional breast MRI.“Although screening mammography is instrumental in our fight against breast cancer, mammography can miss some breast cancers — particularly in women who have dense breast tissue,” said Nicholas J. Petrelli, M.D., Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute. “Offering Fast Breast MRI to women with increased breast density or intermediate breast cancer risk supports a personalized approach to breast health.”Fast Breast MRI is not a replacement for routine screening mammogram. According to the American College of Radiology and American Society of Breast Surgeons, annual screening mammography is recommended starting at age 40.“At Christiana Care, we empower women with information about their breast density and breast cancer risk, provide supplemental breast screening options so women can act on this information and support women in making informed decisions that are right for them,” said Jennifer Rowland, M.D., director of Breast Imaging at the Christiana Care Breast Center.The Christiana Care Breast Center at the Helen F. Graham Cancer Center & Research Institute is among the leading facilities in the region devoted exclusively to breast care, diagnosis and treatment. About the Helen F. Graham Cancer Center & Research Institute The Helen F. Graham Cancer Center & Research Institute, a National Cancer Institute Community Oncology Research Program, is part of the Christiana Care Health System, one of the country’s most dynamic health systems, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. With more than 232,000 patient visits last year, the Graham Cancer Center is recognized as a national model for multidisciplinary cancer care and a top enroller in U.S. clinical research trials. In conjunction with the Gene Editing Institute, the Center for Translational Cancer Research, the Tissue Procurement Center, statewide High-Risk Family Cancer Registry and collaborations with world-renowned scientists at facilities such as The Wistar Institute in Philadelphia scientists are opening new avenues to more quickly translate cancer science into cancer medicine. For more information, visit christianacare.org/cancer.####
Drake’s Organic Spirits Appoints Lyle Berman
to Board of Director
Minneapolis, Minnesota (June 27, 2019) – Drake’s Organic Spirits announced the addition of Lyle Berman, a legendary Minnesota businessman and co-founder of Grand Casinos Inc., to its board of directors effective today.
“We are thrilled to have Lyle join our board of directors and look forward to learning from his decades of experience starting and building successful enterprises,” said Drake’s Organic Spirits Founder/CEO Mark Anderson. “His experience and well-deserved reputation as an entrepreneur, market leader and strategic operator will be invaluable to Drake’s as we look to grow our award-winning line of organic spirits.”
"I am excited about joining the Drake’s board of directors," stated Berman. "I look forward to working alongside Mark Anderson, his management team and my fellow board members to create a strategy that that will bring Drake’s great tasting and sustainable spirits to discerning consumers across the country.”
Berman is credited as one of the early visionaries in the development of casinos outside of the traditional gaming markets of Las Vegas and Atlantic City. He was inducted into the Poker Hall of Fame in 2004 and in 2009 received the Casino Lifetime Achievement Award. Besides Grand Casinos, Inc., he has served as chief executive officer, board member and executive chairman at numerous national companies. Berman currently serves as chairman of Allied Esports, a premiere esports entertainment company he recently launched that will provide world-class in-person experiences, multiplatform content and interactive services to the esports and gaming industries.
About Drake’s Organic Spirits Minneapolis-based Drake’s Organic Spirits was launched in 2017. Drake’s uses the highest quality USDA organic and non-GMO Project Verified ingredients to create a line of ultra- premium spirits. Drake’s Organic Vodka, Drake’s Organic White Rum and Drakes Organic Spiced Rum offer a no grain, no gluten, no gmo, ultra-premium, 12-times distilled handcrafted spirits at a better price than the leading premium brands.
Anova Fertility & Reproductive Health Primed for Growth Following Partnership with Persistence Capital Partners
PCP recognizes Anova's leadership in Canadian fertility as Anova celebrates its third anniversary
TORONTO, June 27, 2019 /CNW/ - Persistence Capital Partners ("PCP"), a private equity fund focused exclusively on investing in high-growth opportunities in Canadian healthcare, is pleased to announce that it is partnering with Anova Fertility & Reproductive Health ("Anova"), providing Anova with capital to accelerate its growth strategy.
Founded three years ago to the day by Dr. Marjorie Dixon, Chief Executive Officer, Anova boasts a state-of-the-art embryology laboratory and a clinic inspired by Dr. Dixon's desire to improve the patient experience and humanize treatment in fertility care. Keeping quality patient care at the forefront, PCP will work closely with Anova's management team on a number of strategic initiatives to support future growth. These initiatives include, opening new clinics, pursuing investment and partnership opportunities, creating a collaborative and 'cutting edge' environment for physicians and other healthcare practitioners, and investing in the best global technologies and techniques to help Canadians grow their families.
"We believe Anova has an exciting growth trajectory ahead and we look forward to working with Dr. Dixon, and her team, to build a leading company in this dynamic market with growth coming from increased awareness, improved technology, improved success rates, and the rising prevalence of infertility in Canadians," said Adrianna Czornyj, Partner at PCP. "Anova has the most sophisticated and proficient lab and the highest patient success rates we've seen in Canada. Our investment is a recognition of the hard work and dedication of the Anova team over the past three years, led by an entrepreneurial physician CEO with a compelling vision for patient care across Canada. We look forward to helping Anova expand its footprint to help more Canadians access patient-centric fertility and reproductive care. I am proud to be working with an organization dedicated to women's health and helping families."
"This is a very exciting time for Anova," added Dr. Dixon. "Assisted fertility can be stressful and disarming. Since day one, we strived to elevate the patient experience by creating a humanizing and caring environment. Now, on the birthday of our clinic's opening, we've received an injection of growth capital to take Anova to the next level. PCP is an ideal partner for us. They have been investing in, running, and growing healthcare businesses in Canada for over 30 years. PCP understands our mission and vision, and they share similar values, including our strong focus on quality and patient care. We endeavored to achieve what was previously deemed impossible in our industry. This culminated in a clinic with a stellar team whose mission was to bring that dream and vision to fruition."
Stuart M. Elman, Managing Partner at PCP, said, "Investing in and supporting game-changing Canadian healthcare businesses is at the core of what PCP does. We are proud to welcome Anova and its team to the PCP group of portfolio companies. Anova is our second investment in our most recent fund, as we continue to execute on our proven investment strategy."
About Persistence Capital Partners
Persistence Capital Partners is Canada's leading private equity fund exclusively focused on high-growth opportunities in the healthcare field. With deep healthcare industry expertise, PCP aims to create significant long-term capital appreciation for its investors by identifying and developing attractive investment opportunities in the Canadian healthcare market. PCP has offices in Montreal, Quebec, and Toronto, Ontario. For more information about Persistence Capital Partners, please visit www.persistencecapital.com, or contact:
Anova Fertility & Reproductive Health opened in 2016 as a full-service fertility and IVF clinic. Anova is Canada's first next-generation embryology laboratory, and is the leader in innovation, education, and communication for high quality patient centric fertility and reproductive care. The team at Anova strives to set the international standard for successful reproductive health and fertility centres, committed to making the right to family accessible to everyone. Anova is known for their culture of support, effective processes and their holistic approach to patient care. For more information about Anova, please visit www.anovafertility.com, or contact:
Dr. Marjorie Dixon Founder, Medical Director, and Chief Executive Officer Anova Fertility & Reproductive Health E: media@anovafertility.com
SOURCE Persistence Capital Partners
ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Data presented at Keystone Symposium on Neurodegenerative Diseases
TORONTO and CAMBRIDGE, MA, June 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data for its lead program, PMN310 for Alzheimer's disease, at last week's Keystone Symposium on Neurodegenerative Diseases. ProMIS' Chief Development Officer Dr. Johanne Kaplan presented data showing that PMN310 possesses superior selectivity for amyloid beta toxic oligomers (AßOs) and improved therapeutic potential compared with other Aß-directed antibodies. Dr. Kaplan shares her perspective on the most notable research stemming from the conference on Episode 8 of the podcast Saving Minds, available on Apple Podcasts and Spotify.
"Researchers from every continent in the world, except Antarctica, lingered far into the evening to view posters, share perspectives and discuss future therapy directions," indicated Dr. Johanne Kaplan, Keystone presenter and Chief Development Officer at ProMIS Neurosciences. "There was genuine optimism and a sense of momentum around therapy development efforts for neurodegenerative diseases. There was a general consensus for the need to selectively target the propagating forms of toxic proteins in pursuit of disease modifying therapies: Our data on PMN310 were very well received."
Dr. Kaplan's poster, "Selective targeting of HHQK conformational epitope in amyloid-beta oligomer species by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer's disease," presented data indicating that PMN310 possesses:
Superior selectivity for toxic AßOs in Alzheimer's brain samples
Ability to neutralize the neurotoxicity and propagation of AßOs
Potential to safely administer high doses of PMN310 (reduced risk of brain edema) and achieve greater therapeutic potency compared with other Aß-directed antibodies.
The conference, Keystone Symposia on Molecular and Cellular Biology, Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, took place June 16-20, 2019 at Keystone Resort in Keystone, Colorado. To access Dr. Kaplan's podcast, Saving Minds, visit iTunes or Spotify.
About ProMIS Neurosciences ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
NEOMED-LABS and Public Health England Announce a Strategic Agreement
LAVAL, QC and PORTON, United Kingdom, June 27, 2019 /CNW Telbec/ - NEOMED-LABS and Public Health England's (PHE) National Infection Service are pleased to announce that they have entered into a strategic partnership to engage in the improvement of global human health. This partnership is focused on vaccine projects with the objective of jointly developing new pre-clinical and clinical assays to support R&D and clinical biopharmaceutical teams in fields such as infectious disease vaccines and immunotherapies.
Although vaccines have fundamentally changed modern medicine, there are still significant challenges to implementing new technologies and expanding expertise to support vaccines development. This agreement allows for the mutual development and transfer of pre-clinical and clinical testing to support a wide range of service offerings to clients. Through joint efforts and expertise, the main objective is to build a universal program to support prophylactic and therapeutic vaccine development from pre-clinical to post-licensure in different fields, including seasonal/pandemic, pediatric and emergent diseases. This collaboration builds on PHE's unique expertise in high-consequence infectious diseases, BSL3, BSL4 and GMP GXP lab services and NEOMED-LABS' capabilities in high-throughput clinical testing.
NEOMED-LABS and PHE's Vaccine Research Groups led by Dr Bassam Hallis have engaged in a collaboration targeting Influenza and Zika aiming at assessing concomitant vaccine responses and are committed to initiating a minimum of three additional collaborative projects before the end of 2019.
"We are thrilled at the prospects opened by this strategic partnership with a venerable and admired institution and the initiation of our collaboration with a team led by such a recognized key opinion leader in the vaccine field. This partnership was made in recognition of PHE's continued advancement of vaccine research for the development of counter measures against emerging and re-emerging diseases. It will give the opportunity for NEOMED-LABS to have a collaborator in Europe and to further expand its offerings, capabilities and coverage.", said Dr Benoit Bouche, NEOMED-LABS President and Chief Executive Officer.
"We have great synergy and complementarity, in terms of our expertise. The ability of NEOMED-LABS to provide high-throughput testing expertise alongside PHE's capabilities in assay development and validation will advance research and development of these needed vaccines to impact human health at a global level.", said Dr Bassam Hallis.
ABOUT NEOMED-LABS
NEOMED-LABS is a leading assay development and specialty clinical laboratory CRO whose versatile team of scientists and technology platforms were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines and soluble large molecules. We proudly provide superior services and unrivaled expertise in immunology based on a client-centric team approach and expedited development time.
PHE exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through advocacy, partnerships, world-class science, knowledge and intelligence, and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health and Social Care.
For more information on PHE visit www.gov.uk/phe or follow us on Twitter @PHE_uk
STATEMENT - One More Patient Seen - One Less Patient Waiting
TORONTO, June 27, 2019 /CNW/ - Dr. Sohail Gandhi, President, Ontario Medical Association issued the following statement this morning.
"I am proud to be the President of Ontario's 31,500 practising physicians. I know that making sure every patient gets the care they need, when they need it is every physician's top priority. We are on the frontlines of the health care system, caring for 340,000 patients every day.
Ontario is undergoing a much needed, and absolutely necessary health care transformation. Our population continues to grow and age and people's health care needs are increasing in their complexity. All across the province, doctors are working hard to care for more patients and reduce wait times.
Under our health care system, doctors are independent contractors who own their own practices and operate as small businesses. Physician services depend entirely on patient need, and that varies from community to community, specialty to specialty, and physician to physician.
Doctors bill for patients they see, procedures they perform, and in some cases, the tests they interpret. It is important to note that the amount a doctor bills is neither their salary nor their take-home pay. Physicians must pay for the costs of operating their practices, from staff, to rent, to medical and office supplies. These expenses take up a significant proportion of billings, in some specialties up to 50%.
There are also many different models for practices. Some are small and have limited staff while some have a much larger team of several types of health professionals including: physician assistants, nurses, nurse practitioners, technicians and medical assistants. Expenses and volumes of patients seen would be very different depending on the operating model.
A physician's annual gross billing amount reflects demand for treatment. The more patients need services, the more OHIP is billed for those services. This demand may be intensified in remote and rural locations where there are limited medical resources. In fact, many physicians in underserviced communities may work 7 days a week to provide the best care for their patients.
It is also important to note that Ontario continues to have a lower number of physicians than most other jurisdictions in the world. We currently have 2.6 physicians for every 1,000 patients, whereas Germany has about 4 physicians for every 1,000 patients. This means that our physicians have to see more patients (and thus bill more) to help keep the residents of Ontario healthy.
The OMA supports greater transparency of physician billings. But this should include appropriate context for the public and be governed by an Act of Legislature as it is in other provinces. The real value in greater transparency is to show how much patient demand there is for services. Looking at a select 0.3% of physicians will not do this.
Ontario's doctors are working with the government to fix our health care system, solve critical issues like hallway medicine and deliver the high-quality care our patients deserve. Part of this work is to recognize the value of services patients need and how those services are provided. We will continue to do this work with the government going forward.
Each and every billing submitted by a doctor means that one more patient has been treated and one less patient is waiting."
About the OMA
The Ontario Medical Association is a membership organization that represents the political, clinical and economic interests of doctors in Ontario. Our 41,000 members are practicing and retired doctors, residents and medical students.
SOURCE Ontario Medical Association
ProMIS Neurosciences Closing Private Placement
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
TORONTO, June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it is closing today a private placement of 4,680,000 units (the "Units") at a price of CDN$0.25 (or US$0.1875) per Unit (the "Offering Price") for gross proceeds of approximately CDN$1,170,000 (the "Offering").
"We are pleased with the completion of this private placement", stated Dr. Elliot Goldstein, ProMIS President and CEO. "The additional funds coupled with our conservative expenditure management support a cash runway into late 2019."
Each Unit consists of one common share of the Company (each a "Share") and one share purchase warrant of the Company (each a "Warrant"). Each Warrant entitles the holder thereof to purchase one Share ("a "Warrant Share") at an exercise price of $0.35 per Warrant Share at any time for five years.
All securities issued in connection with the Offering will be subject to a four-month statutory hold period in accordance with applicable securities laws. Net proceeds from the Offering are intended to be used for working capital and general corporate purposes. Closing of the Offering is subject to TSX approval.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
For further information:
For media inquiries, please contact: Shanti Skiffington, shanti.skiffington@gmail.com, Tel. 617 921-0808; For Investor Relations, please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, nick@alpineequityadv.com, Tel. 617 901-0785
ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform
VICTORIA, June 26, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that from this point forward it will guarantee the success of campaigns powered by its proprietary B cell Select™ Antibody Discovery platform.
Pioneering innovative antibody discovery, ImmunoPrecise harnesses its species agnostic platform, driven by scientific experts with over a decade of experience in single B cell services, to leverage its already industry-wide, unprecedented success rates.
B cell technologies is a space where IPA has spent years differentiating itself from competitors. The Company understands the importance to ensure clients can readily ascertain who has the depth of experience and proven success to partner with pharma, without jeopardizing outcomes.
It can be to the detriment of pharmaceutical partners and patients when therapeutic programs are continually repeated due to low success rates, oftentimes a result of contract organizations' lack of experience in modern technologies, which can take years to master, or their use of outdated platforms.
"We believe that backing our expertise with a success guarantee, in a royalty-free service offering, aligns our B Cell Select™ platform with the goals of our clients worldwide", stated IPA President and CEO, Dr. Jennifer Bath. "Ultimately, our optimized platform, exhibiting a minimum 94% success rate, along with our success guarantee, decreases turnaround time, attenuates risk, and reduces the overall cost for our clients in getting antibody therapeutics to the clinic. We are both humbled and honored to be servicing this niche."
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at ImmunoPrecise Antibodies Europe (formerly ModiQuest Research), in Oss, and U-Protein Express, in Utrecht, both in the Netherlands. The Company operates globally to offer a continuum of superior antibody services, from target analysis to pre-clinical studies.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
For further information:
For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email: frederick@contactfinancial.com, Contact Financial Corp., 1450 – 701 West Georgia St., Vancouver, BC V7Y 1G5
For Chiropractors, Naturopaths, Acupuncturists and Medical Doctors, Functional Medicine Offers a Short Path to a “Go-to” Reputation
Greer, SC, June 25th,2019 – For health care practitioners hoping to carve out a local reputation for achieving remarkable results with patients, a relatively new diagnostic paradigm called Functional Medicine provides a promising route. At Functional Medicine University (www.functionalmedicineuniversity.com), where training in Functional Medicine builds on practitioners’ previous medical education, after just six to eight months graduates are often able to begin building a reputation for helping patients who had nearly given up hope. “By looking at the whole patient and at data from advanced laboratory tests, Functional Medicine practitioners can frequently diagnose and treat difficult cases that have stumped other health care professionals,” says Dr. Ron Grisanti, D.C., a leading advocate of Functional Medicine and director of the Functional Medicine University program. “Their success rate with hard cases in turn leads to strong patient loyalty and increased referrals from patients and other practitioners. It’s also relatively easy for our graduates to receive local media coverage because Functional Medicine is still new to the general public.” Functional Medicine University’s holistic training involves rigorous modules on the GI system, the effects of stress, the immune system, the endocrine system, inflammation, detoxification, nutrition and more. Continuing education credits are available for physicians, chiropractors, naturopaths, acupuncturists, osteopaths, nurses, nurse practitioners, dieticians, pharmacists and dentists. Training occurs through teleseminars, webinars, online videos, textual material, clinical case conference calls, one-on-one coaching and an interactive private forum for those in the program. The next training session, which costs $2,495, begins in July 2019. For more information or to be added to the notification list for potential enrollees in the program, health care professionals should visit www.functionalmedicineuniversity.com. About Functional Medicine UniversityFounded in 2006 by Dr. Ron Grisanti, D.C., Functional Medicine University is the oldest online Functional Medicine certification training school, serving healthcare professionals from 81 countries and all 50 US states. Functional Medicine emphasizes scientific diagnosis of an individual’s unique biochemical relationships, then encouraging the body to rebalance itself naturally instead of through surgery or drugs. Founder/director Dr. Grisanti is a board certified chiropractic orthopedist with a master's degree in nutritional science from the University of Bridgeport. He also holds a diplomate degree with the American Clinical Board of Nutrition.
New Technology Platforms Dramatically Increase Cannabinoid Yields
LOS ALAMOS, NM, June 25, 2019 — Trait Biosciences Inc. ("Trait" or the "Company"), the largest integrated bio-technology innovator in the cannabis industry, today announced the US Patent and Trademarks Office (“USPTO”) has allowed it patent protection for breakthrough technology platforms that produce truly water-soluble cannabinoids and dramatically increase cannabinoid yields in hemp and cannabis.
The USPTO granted allowance for the Company’s Patent Application 16/110,728 entitled “High Level In Vivo Biosynthesis and Isolation of Water-Soluble Cannabinoids in Plant Systems” (the “Patent”). The Patent, which was applied for in August 2018 and allowed in just under one year, gives Trait robust protection over all key technological components for its Distilled™ and Amplified™ technologies.
“This is another pivotal day for us,” said Dr. Richard Sayre, Chief Science Officer of Trait. “The allowance of this Patent gives us robust protection over two of our platform technologies — TraitDistilled™ and Trait Amplified™ — which, we are confident, will change the future of the cannabis and hemp industries.”
Sayre added: “What makes the allowance of this Patent more gratifying is the scope of protection that the USPTO has given us — the Patent covers every gene/enzyme from allorganisms claimed in the Patent. It is uncommon for the USPTO to grant such broad protection over classes of genes and enzymes in this manner. It is a testament to the hard work, innovation and experience of our science team, and the excellent IP strategy that has been developed by our IP counsel.”
TraitDistilled™ is the Company’s proprietary technology that uses a natural process to convert fat-soluble cannabinoids into cannabinoids that are tasteless, odorless, fully soluble in water and have higher bioavailability than fat-soluble cannabinoids. These characteristics make Trait Distilled™ cannabinoids ideal for use in cannabis and hemp beverages and other products because they are an alternative to the current industry reliance on nano- and micro-emulsion particle technologies. Regulators such as Health Canada, the European Union and the OECD are expressing concern about the use of nanotechnologies, and potentially harmful impacts to human health.
“These patented platforms reinforce Trait's leadership in providing the Hemp and Cannabis Industry the innovative technology needed to develop high-quality products that consumers can trust," added Trait Chief Executive Officer Peter McDonough. "We're excited to provide our partners the breakthrough solutions associated with this science, which offers a powerful competitive advantage in product development."
Trait Amplified™increases plant trichome production, and offers greater photosynthetic efficiency, resulting in cannabinoid yield increases of 2x to 5x higher than conventional plants. Amplified™ also allows plants to produce water-soluble cannabinoids within the plant itself, enabling the extraction of cannabinoids through simple, water-based extraction techniques. This can replace high-intensity, solvent-based extraction techniques that use toxic chemicals, which can leave unwanted residues.
“The breadth of protection granted to us in this Patent will preclude competitors from attempting to mimic our technologies by using alternative genes to achieve the same outcomes,” added Ronan Levy, Chief Strategy Officer at Trait. “It also confirms what we have long expected — that the technologies we are developing at Trait are extremely novel and light years ahead of what the rest of the industry is doing, and offer a dramatic competitive advantage.”
The Company is currently in discussions with potential partners to scale up production of its Trait Distilled™ cannabinoids.
About Trait Biosciences
With a team of internationally recognized scientists who are applying best-in-class technology and agricultural science, Trait Biosciences is a global biotechnology leader in the hemp and cannabis industries. Its consumer technology platforms provide breakthrough IP and science which produce enhanced cannabinoids featuring predictable onset timing, superior bioavailability, extended stability and improved taste. Trait's technologies include a process for generating water-soluble cannabinoids that eliminates the need for emulsion or nanotechnology. The company is providing advanced agricultural technologies to increase crop yields and plant safety, including ultrahigh yield Amplified™ plants which dramatically increase a plant's natural cannabinoid productivity, and its Defence™ RNAi crop protection technology, which eliminates the need for pesticides or fungicides, providing higher quality safer CBD infused nutraceutical and pharmaceutical products.
Cautionary Statement on Forward-Looking Information
Certain information contained in this press release, including any information as to Trait Bioscience Inc.'s (the "Corporation") strategy, projects, plans or future financial or operating performance, constitutes "forward-looking statements". All statements, other than statements of historical fact, are forward-looking statements. The words "will", "expect", "continue", "assess", "anticipate" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions; including material estimates and assumptions that, while considered reasonable by the Corporation as at the date of this press release in light of each of management's experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information.
Any forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Although management of the Corporation believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
